What is the recommended immediate and short‑term management after administering tenecteplase (TNK) for acute ischemic stroke?

Post-Tenecteplase Management for Acute Ischemic Stroke

After administering tenecteplase for acute ischemic stroke, immediately monitor for bleeding complications and orolingual angioedema, avoid all invasive procedures for several hours, delay aspirin for 24 hours, and obtain repeat neuroimaging before starting any antiplatelet therapy. 1, 2

Immediate Post-Administration Monitoring (First Hours)

Bleeding Surveillance

• Avoid all intramuscular injections and minimize patient handling for the first few hours following tenecteplase administration 3
• Perform arterial and venous punctures only when absolutely required; avoid internal jugular and subclavian venous punctures to minimize bleeding from noncompressible sites 3
• If arterial puncture is necessary, use an upper extremity vessel accessible to manual compression and apply pressure for at least 30 minutes 3
• Monitor continuously for signs of intracranial hemorrhage, gastrointestinal bleeding, or bleeding from any site 3

Airway and Angioedema Management

• Monitor closely for orolingual angioedema, which can develop rapidly within 30 minutes of tenecteplase administration 4
• If angioedema develops:
  • Discontinue any ACE inhibitors immediately 4
  • Administer IV methylprednisolone 125 mg, IV diphenhydramine 50 mg, and ranitidine 50 mg IV or famotidine 20 mg IV 4
  • If angioedema progresses, give epinephrine 0.3 mL (0.1%) subcutaneously or by nebulizer 4
  • Endotracheal intubation may not be necessary if edema is limited to anterior tongue and lips, but edema involving larynx, palate, floor of mouth, or oropharynx poses higher risk and may require awake fiberoptic intubation 4

Blood Pressure Management

• Maintain blood pressure control below 185/110 mmHg during and after thrombolysis to minimize hemorrhagic transformation risk 1, 2

Neuroimaging and Hemorrhage Assessment

Repeat Imaging Timing

• Obtain repeat neuroimaging (non-contrast CT or MRI) at 24 hours after tenecteplase administration to exclude hemorrhagic transformation before initiating antiplatelet therapy 1
• If clinical deterioration occurs at any time, perform immediate neuroimaging to assess for intracranial hemorrhage 4

Management of Symptomatic Hemorrhage

• If serious bleeding occurs that is not controlled by local pressure, immediately discontinue any concomitant heparin or antiplatelet agents 3
• The absolute increase in symptomatic intracranial hemorrhage with thrombolysis is approximately 6% (7% with thrombolysis vs 1% without) 1

Antiplatelet Therapy Initiation

Aspirin Timing

• Delay aspirin administration for 24 hours after tenecteplase 4, 1
• After 24 hours and confirmation of no hemorrhagic transformation on repeat imaging, administer aspirin 160-300 mg 4
• Aspirin should be given within 24-48 hours after stroke onset once hemorrhage is excluded 4
• Aspirin is not a substitute for acute stroke treatment and should never delay tenecteplase or mechanical thrombectomy 4

Alternative Antiplatelet Considerations

• In patients with aspirin contraindication, alternative antiplatelet agents may be reasonable after the 24-hour window 4
• For minor stroke patients, dual antiplatelet therapy (aspirin plus clopidogrel) for 21 days can be beneficial for early secondary stroke prevention, but this should be initiated only after excluding hemorrhage 4

Anticoagulation Management

Immediate Post-Thrombolysis Period

• Do not initiate therapeutic anticoagulation during the immediate post-thrombolysis period; aspirin is preferred over therapeutic parenteral anticoagulants 1
• The timing of anticoagulation initiation should balance individual risk versus benefit, but generally avoid within the first 24 hours 4

VTE Prophylaxis

• For patients with restricted mobility, initiate prophylactic-dose low-molecular-weight heparin or intermittent pneumatic compression to prevent secondary venous thromboembolism 1
• This prophylactic dosing is distinct from therapeutic anticoagulation and can be considered earlier 1

Endovascular Therapy Coordination

Workflow Advantages

• The single-bolus administration of tenecteplase (versus 1-hour alteplase infusion) offers significant workflow advantages when coordinating endovascular therapy or patient transfer 1, 2
• Do not delay or skip tenecteplase in patients eligible for both thrombolysis and thrombectomy; patients should receive tenecteplase even if endovascular therapy is planned 1
• For large vessel occlusion strokes, tenecteplase 0.25 mg/kg is preferable to skipping thrombolysis before mechanical thrombectomy, even in direct admission to thrombectomy-capable centers 5

Monitoring for Reperfusion-Related Complications

Arrhythmia Surveillance

• Have anti-arrhythmic therapy available for bradycardia and ventricular irritability, as coronary thrombolysis may result in reperfusion arrhythmias (sinus bradycardia, accelerated idioventricular rhythm, ventricular premature depolarizations, ventricular tachycardia) 3
• While this FDA warning is based on cardiac indications, vigilance for arrhythmias is prudent in stroke patients as well 3

Hypersensitivity Reactions

• Monitor for several hours after infusion for hypersensitivity reactions including urticaria, anaphylaxis, angioedema, laryngeal edema, and rash 3
• If hypersensitivity symptoms occur, initiate antihistamines and corticosteroids 3

Common Pitfalls to Avoid

• Never administer aspirin or other antiplatelet agents before 24-hour repeat imaging confirms absence of hemorrhagic transformation 4, 1
• Never use the pulmonary embolism dose (0.5 mg/kg) or STEMI dose for stroke patients; the stroke dose is 0.25 mg/kg (maximum 25 mg) 2, 6
• Do not perform unnecessary invasive procedures (arterial lines, central lines, Foley catheters) during the first several hours after thrombolysis 3
• Avoid dextrose-containing IV solutions, as tenecteplase precipitates with dextrose; flush lines with normal saline before and after administration 3